在评估基于病毒载体的候选疟疾疫苗方案之前，对黑猩猩腺病毒63型中和抗体进行评估。
Assessment of chimpanzee adenovirus serotype 63 neutralizing antibodies prior to evaluation of a candidate malaria vaccine regimen based on viral vectors.
作者信息
Nébié Issa, Edwards Nick J, Tiono Alfred B, Ewer Katie J, Sanou Guillaume S, Soulama Issiaka, Sanon Souleymane, Diarra Amidou, Yaro Jean Baptiste, Kangoye David, Imoukhuede Egeruan B, Hill Adrian V S, Sirima Sodiomon B
机构信息
Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso
Centre for Clinical Vaccinology and Tropical Medicine and the Jenner Institute Laboratories, University of Oxford, Oxford, United Kingdom.
出版信息
Clin Vaccine Immunol. 2014 Jun;21(6):901-3. doi: 10.1128/CVI.00723-13. Epub 2014 Apr 16.
Abstract
Prior to a chimpanzee adenovirus-based (ChAd63) malarial vaccine trial, sera were collected to assess ChAd63-specific neutralizing antibody titers in Banfora (Burkina Faso). The low neutralizing antibody titers reported in both adults and children (median titers, 139.1 and 35.0, respectively) are encouraging for the potential use of ChAd63 as a malarial vaccine vector.
摘要
在一项基于黑猩猩腺病毒（ChAd63）的疟疾疫苗试验之前，采集了血清以评估布基纳法索班福拉地区针对ChAd63的中和抗体滴度。成人和儿童中报告的低中和抗体滴度（中位数滴度分别为139.1和35.0）对于ChAd63作为疟疾疫苗载体的潜在用途而言是令人鼓舞的。
相似文献
1
Assessment of chimpanzee adenovirus serotype 63 neutralizing antibodies prior to evaluation of a candidate malaria vaccine regimen based on viral vectors.在评估基于病毒载体的候选疟疾疫苗方案之前，对黑猩猩腺病毒63型中和抗体进行评估。
Clin Vaccine Immunol. 2014 Jun;21(6):901-3. doi: 10.1128/CVI.00723-13. Epub 2014 Apr 16.
2
Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy.在疫苗载体效力背景下，肯尼亚儿童中针对黑猩猩腺病毒63型和人腺病毒5型的血清中和抗体流行情况。
Vaccine. 2009 Jun 2;27(27):3501-4. doi: 10.1016/j.vaccine.2009.03.080. Epub 2009 Apr 16.
3
Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector.临床评估重组猿猴腺病毒 ChAd63：一种有效的新型疫苗载体。
J Infect Dis. 2012 Mar 1;205(5):772-81. doi: 10.1093/infdis/jir850. Epub 2012 Jan 24.
4
Adenovirus type 4 and 7 vaccination or adenovirus type 4 respiratory infection elicits minimal cross-reactive antibody responses to nonhuman adenovirus vaccine vectors.4型和7型腺病毒疫苗接种或4型腺病毒呼吸道感染引发的针对非人腺病毒疫苗载体的交叉反应性抗体反应极小。
Clin Vaccine Immunol. 2014 May;21(5):783-6. doi: 10.1128/CVI.00011-14. Epub 2014 Mar 12.
5
Seroprevalence of Neutralizing Antibodies against Human Adenovirus Type-5 and Chimpanzee Adenovirus Type-68 in Cancer Patients.癌症患者中针对人腺病毒 5 型和黑猩猩腺病毒 68 型的中和抗体的血清流行率。
Front Immunol. 2018 Mar 7;9:335. doi: 10.3389/fimmu.2018.00335. eCollection 2018.
6
Seroprevalence of neutralizing antibodies to human adenoviruses type-5 and type-26 and chimpanzee adenovirus type-68 in healthy Chinese adults.健康中国成年人中针对人腺病毒 5 型和 26 型以及黑猩猩腺病毒 68 型的中和抗体血清阳性率。
J Med Virol. 2013 Jun;85(6):1077-84. doi: 10.1002/jmv.23546.
7
Neutralizing antibodies to human and simian adenoviruses in humans and New-World monkeys.人体和新世界猴体内针对人腺病毒和猴腺病毒的中和抗体。
Virology. 2010 Nov 10;407(1):1-6. doi: 10.1016/j.virol.2010.07.043. Epub 2010 Aug 24.
8
A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity.一种新型低人血清流行率的黑猩猩腺病毒载体：改进的载体衍生系统和比较免疫原性。
PLoS One. 2012;7(7):e40385. doi: 10.1371/journal.pone.0040385. Epub 2012 Jul 13.
9
Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal.在塞内加尔成年人中，采用编码ME-TRAP的ChAd63和MVA进行初免-加强免疫接种预防恶性疟原虫感染的安全性、免疫原性和有效性。
PLoS One. 2016 Dec 15;11(12):e0167951. doi: 10.1371/journal.pone.0167951. eCollection 2016.
10
Development of novel vaccine vectors: Chimpanzee adenoviral vectors.新型疫苗载体的开发：黑猩猩腺病毒载体。
Hum Vaccin Immunother. 2018 Jul 3;14(7):1679-1685. doi: 10.1080/21645515.2017.1419108. Epub 2018 Jan 23.
引用本文的文献
1
The seroprevalence of adenoviruses since 2000.2000年以来腺病毒的血清流行率。
Emerg Microbes Infect. 2025 Dec;14(1):2475831. doi: 10.1080/22221751.2025.2475831. Epub 2025 Mar 17.
2
Understanding Post Entry Sorting of Adenovirus Capsids; A Chance to Change Vaccine Vector Properties.了解腺病毒衣壳的进入后分拣；改变疫苗载体特性的机会。
Viruses. 2021 Jun 24;13(7):1221. doi: 10.3390/v13071221.
3
First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children.首个 ChAd63 MVA ME-TRAP 载体疟疾疫苗候选物在 5-17 月龄婴儿和儿童中的现场疗效试验。
PLoS One. 2018 Dec 12;13(12):e0208328. doi: 10.1371/journal.pone.0208328. eCollection 2018.
4
Adenovirus-prime and baculovirus-boost heterologous immunization achieves sterile protection against malaria sporozoite challenge in a murine model.腺病毒初免和杆状病毒加强的异源免疫在小鼠模型中实现了对疟原虫孢子虫挑战的无菌保护。
Sci Rep. 2018 Mar 1;8(1):3896. doi: 10.1038/s41598-018-21369-y.
5
Vaccine vectors based on Adenovirus 19a/64 exhibit broad cellular tropism and potently restimulate HCMV-specific T cell responses ex vivo.基于腺病毒 19a/64 的疫苗载体具有广泛的细胞嗜性，并能有效地在体外重新刺激 HCMV 特异性 T 细胞反应。
Sci Rep. 2018 Jan 24;8(1):1474. doi: 10.1038/s41598-018-19874-1.
6
Vector-based genetically modified vaccines: Exploiting Jenner's legacy.基于载体的基因改造疫苗：利用詹纳的遗产。
Vaccine. 2016 Dec 7;34(50):6436-6448. doi: 10.1016/j.vaccine.2016.06.059. Epub 2016 Oct 28.
7
Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal.在塞内加尔成年人中，采用编码ME-TRAP的ChAd63和MVA进行初免-加强免疫接种预防恶性疟原虫感染的安全性、免疫原性和有效性。
PLoS One. 2016 Dec 15;11(12):e0167951. doi: 10.1371/journal.pone.0167951. eCollection 2016.
8
Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations.将以ChAd63和MVA ME-TRAP进行的初免-加强免疫的免疫原性从无疟疾人群转化至疟疾流行地区人群。
Mol Ther. 2014 Nov;22(11):1992-2003. doi: 10.1038/mt.2014.109. Epub 2014 Jun 16.
本文引用的文献
1
Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. chimpanzee 腺病毒-MVA 免疫诱导的对人疟疾的保护性 CD8+ T 细胞免疫。
Nat Commun. 2013;4:2836. doi: 10.1038/ncomms3836.
2
A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity.一种新型低人血清流行率的黑猩猩腺病毒载体：改进的载体衍生系统和比较免疫原性。
PLoS One. 2012;7(7):e40385. doi: 10.1371/journal.pone.0040385. Epub 2012 Jul 13.
3
Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector.临床评估重组猿猴腺病毒 ChAd63：一种有效的新型疫苗载体。
J Infect Dis. 2012 Mar 1;205(5):772-81. doi: 10.1093/infdis/jir850. Epub 2012 Jan 24.
4
Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species.来源于大量猿猴腺病毒的疫苗载体在多种物种中诱导强烈的细胞免疫。
Sci Transl Med. 2012 Jan 4;4(115):115ra2. doi: 10.1126/scitranslmed.3002925.
5
Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man.新型腺病毒疫苗可诱导人体对 HCV 产生广泛而持久的 T 细胞应答。
Sci Transl Med. 2012 Jan 4;4(115):115ra1. doi: 10.1126/scitranslmed.3003155.
6
Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors.恶性疟原虫血期抗原 MSP1 在 ChAd63 和 MVA 疫苗载体中的 I 期临床评估。
Mol Ther. 2011 Dec;19(12):2269-76. doi: 10.1038/mt.2011.176. Epub 2011 Aug 23.
7
Neutralizing antibodies to human and simian adenoviruses in humans and New-World monkeys.人体和新世界猴体内针对人腺病毒和猴腺病毒的中和抗体。
Virology. 2010 Nov 10;407(1):1-6. doi: 10.1016/j.virol.2010.07.043. Epub 2010 Aug 24.
8
Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy.在疫苗载体效力背景下，肯尼亚儿童中针对黑猩猩腺病毒63型和人腺病毒5型的血清中和抗体流行情况。
Vaccine. 2009 Jun 2;27(27):3501-4. doi: 10.1016/j.vaccine.2009.03.080. Epub 2009 Apr 16.
9
Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei.猿猴腺病毒载体对伯氏疟原虫的单剂量免疫原性和保护效力
Eur J Immunol. 2008 Mar;38(3):732-41. doi: 10.1002/eji.200737672.
10
Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa.撒哈拉以南非洲地区个体中腺病毒特异性中和抗体滴度的年龄依赖性
J Clin Microbiol. 2006 Oct;44(10):3781-3. doi: 10.1128/JCM.01249-06.
Zotero 插件